


**FIGURA 1**




FIGURA 2

CD3 scFv de baja afinidad: 1G4




FIGURA 3




FIGURA 4

Actividad de hz45G10 emparejado con un CD3 scFv de alta
o baja afinidad




FIGURA 5

Actividad de hz45G10 emparejado con un CD3 scFv de
alta o baja afinidad




FIGURA 6




FIGURA 7

Citotoxicidad con linfocitos T expandidos (TDCC)




FIGURA 8




FIGURA 9




FIGURA 10

Citotoxicidad con linfocitos T expandidos (TDCC)




FIGURA 11

Citotoxicidad con PBMC vírgenes




FIGURA 12

TDCC contra células OCI-AML-2




FIGURA 13




FIGURA 14

Citotoxicidad de PBMC contra células OCI-AML-2




FIGURA 15




FIGURA 16

TDCC contra células THP-1 con inactivación de ILT3




FIGURA 17

Liberación de citocinas con Ab recubiertos




FIGURA 18

Liberación de citocinas con Ab solubles




FIGURA 19

Liberación de citocinas con Ab recubiertos




FIGURA 20




FIGURA 21




FIGURA 22




FIGURA 23





FIGURA 24

**FIGURA 25**




FIGURA 26




FIGURA 27




FIGURA 28




FIGURA 29

Citotoxicidad contra basófilos KU812




FIGURA 30

Citotoxicidad contra basófilos LAMA84




FIGURA 31

Citotoxicidad con linfocitos T expandidos (TDCC) y líneas celulares de mieloma múltiple

Células diana MM1S




FIGURA 32

Citotoxicidad con linfocitos T expandidos (TDCC) y líneas celulares de mieloma múltiple




FIGURA 33

Citotoxicidad con linfocitos T expandidos (TDCC) y líneas celulares de mieloma múltiple




FIGURA 34

Esquema de tratamiento y cuantificación de carga tumoral en modelos de AML de ratón




FIGURA 35




FIGURA 36




FIGURA 37




FIGURA 38





FIGURA 39

**ABX1446 disminuyó la carga tumoral circulante en
ratones humanizados CD34+**



Animales administrados con las moléculas
indicadas a 1 mpk

FIGURA 40




FIGURA 41




FIGURA 42




FIGURA 43




FIGURA 44